A Phase 2 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 14 that started in 2011, is one of 5 in phase 2, and was the 56th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 104th largest by enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2011, is one of 20 in phase 2, and was the 119th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time. Patients will be randomized to 8 mg/kg RoActemra/Actemra infusion of 31 minutes every 4 weeks or to RoActemra/Actemra 8 mg/kg infusion of 60 minutes every 4 weeks. The anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
Drug: Tocilizumab
Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
Drug: Tocilizumab
8 mg/kg infusion
Also known as: RoActemra, Actemra
Percentage of Participants With Any Infusion Reaction
An infusion reaction was defined as any adverse event (AE) that occurred during the infusion or during the 24 hours following the infusion and deemed possibly or probably related to tocilizumab.
Time frame: Baseline (Day 1), and Weeks 4, 8, 12, 16, and 20
Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)
All occurrences of participants who received at least 1 infusion of tocilizumab and then stopped tocilizumab infusions due to an AE or SAE were analyzed.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Discontinuing Tocilizumab for Other Reasons
Participants that stopped the administration of tocilizumab and discontinued the study prematurely due to reasons other than an AE or SAE were analyzed.
Time frame: Baseline and Weeks, 4, 8, 12, 16, 20, and 24
Percentage of Participants With Increased Liver Enzyme Values of Greater Than (>)1.5 Times, or >3 Times, or >5 Times Over the Upper Limit of Normal (ULN) by Visit Among Participants Who Completed All Visits
Increased liver enzyme values defined as Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) values of \>1.5 times, or \>3 times, or \>5 times over the ULN. Almost none of the participants had increased measurements of AST, thus only values of ALT were presented. None of the participants presented with increased values of ALT above 3 or 5 ULN at any of the visits. ITT Completers is defined as a subset of the participants in the ITT population who completed all study visits.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants With Increased Lipid Values by Visit Among Participants Who Completed All Visits
Increased levels of high density lipoproteins (HDL) equal to or greater than (≥)1.5 millimoles per liter (mmol/L), and low density lipoproteins (LDL) ≥4.1 mmol/L, and total cholesterol ≥5.1 mmol/L, are defined according to the Adult Treatment Panel III (ATP-III) guidelines.
Time frame: Screening and Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants With a Reduction of at Least 1.2 Points in Disease Activity Score Based on 28-Joint Count (DAS28) by Visit Among Participants Who Completed All Visits
Improvement in Rheumatoid Arthritis (RA) disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response High sensitivity C-Reactive Protein (hsCRP), and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score less than (\<)3.2, and remission was defined as a DAS28 score \<2.6.
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving a DAS28 Score Below 3.2 (Low Disease Activity) by Visit Among Participants Who Completed All Visits
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving a DAS28 Score Below 2.6 (Remission) by Visit Among Participants Who Completed All Visits
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
Time frame: Weeks 4, 8, 12, 16, 20, and 24
DAS28 Score by Visit Among Participants Who Completed All Visits
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
Time frame: Baseline, Weeks, 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) Improvement (ACR20 Response) by Visit Among Participants Who Completed All Visits
ACR20 response is defined as an improvement of ≥20% in swollen joint count (SJC; 66 joints) and tender joint count (TJC; 68 joints) as well as ≥20% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and acute phase reactive factors (Erythrocyte Sedimentation Rate \[ESR\] or C-Reactive Protein \[CRP\]).
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving ACR 50% Improvement (ACR50 Response) by Visit Among Participants Who Completed All Visits
ACR50 response is defined as an improvement of ≥50% in SJC (66 joints) and TJC (68 joints) as well as ≥50% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
Time frame: Weeks, 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving ACR 70% Improvement (ACR70 Response) by Visit, Among Participants Who Completed All Visits
ACR70 response is defined as an improvement of ≥70% in SJC (66 joints) and TJC (68 joints) as well as ≥70% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving ACR 90% Improvement (ACR90 Response) by Visit Among Participants Who Completed All Visits
ACR90 response is defined as an improvement of ≥90% in SJC (66 joints) and TJC (68 joints) as well as ≥90% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
Time frame: Weeks 4, 8, 12, 16, 20 and 24
High Sensitivity C-Reactive Protein (hsCRP) Levels by Visit Among Participants Who Completed All Visits
hsCRP is a marker for inflammation and is measured in milligrams per liter (mg/L). High levels of this protein indicate inflammation in diseases such as RA.
Time frame: Screening, Baseline, Weeks 4, 8, 12, 16, 20, and 24
Modified Health Assessment Questionnaire (M-HAQ) Score by Visit Among Participants Who Completed All Visits
M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.
Time frame: Baseline, Weeks 4, 8, 12, 20, and 24
Percentage of Participants With Improvement of at Least 0.22 Units in M-HAQ Compared to Baseline Per Visit Among Participants Who Completed All Visits
M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.
Time frame: Weeks 4, 8. 12, 20, and 24
| Milestone | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Started | 22 | 25 |
| Completed | 18 | 22 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
An infusion reaction was defined as any adverse event (AE) that occurred during the infusion or during the 24 hours following the infusion and deemed possibly or probably related to tocilizumab.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Percentage of Participants With Any Infusion Reaction | 13.6 | 12.0 |
All occurrences of participants who received at least 1 infusion of tocilizumab and then stopped tocilizumab infusions due to an AE or SAE were analyzed.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE) | 9.0 | 8.0 |
Participants that stopped the administration of tocilizumab and discontinued the study prematurely due to reasons other than an AE or SAE were analyzed.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Percentage of Participants Discontinuing Tocilizumab for Other Reasons | 9 | 4 |
Increased liver enzyme values defined as Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) values of \>1.5 times, or \>3 times, or \>5 times over the ULN. Almost none of the participants had increased measurements of AST, thus only values of ALT were presented. None of the participants presented with increased values of ALT above 3 or 5 ULN at any of the visits. ITT Completers is defined as a subset of the participants in the ITT population who completed all study visits.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| ALT>1.5 ULN, Week 4 | 12 | 5 |
| ALT>1.5 ULN, Week 8 | 6 | 10 |
| ALT>1.5 ULN, Week 12 | 6 | 5 |
| ALT>1.5 ULN, Week 16 | 6 | 10 |
| ALT>1.5 ULN, Week 20 | 12 | 5 |
| ALT>1.5 ULN, Week 24 | 24 | 5 |
Increased levels of high density lipoproteins (HDL) equal to or greater than (≥)1.5 millimoles per liter (mmol/L), and low density lipoproteins (LDL) ≥4.1 mmol/L, and total cholesterol ≥5.1 mmol/L, are defined according to the Adult Treatment Panel III (ATP-III) guidelines.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| High HDL (≥1.5 mmol/L), Screening | 44 | 46 |
| High HDL (≥1.5 mmol/L), Week 4 | 44 | 55 |
| High HDL (≥1.5 mmol/L), Week 8 | 50 | 36 |
| High HDL (≥1.5 mmol/L), Week 12 | 39 | 50 |
| High HDL (≥1.5 mmol/L), Week 16 | 44 | 41 |
| High HDL (≥1.5 mmol/L), Week 20 | 39 | 36 |
| High HDL (≥1.5 mmol/L), Week 24 | 44 | 46 |
| High LDL (≥4.1 mmol/L), Screening | 0 | 14 |
| High LDL (≥4.1 mmol/L), Week 4 | 11 | 27 |
| High LDL (≥4.1 mmol/L), Week 8 | 6 | 32 |
| High LDL (≥4.1 mmol/L), Week 12 | 6 | 36 |
| High LDL (≥4.1 mmol/L), Week 16 | 6 | 23 |
| High LDL (≥4.1 mmol/L), Week 20 | 11 | 32 |
| High LDL (≥4.1 mmol/L), Week 24 | 6 | 18 |
| High total cholesterol (≥5.1 mmol/L), Screening | 33 | 59 |
| High total cholesterol (≥5.1 mmol/L), Week 4 | 56 | 73 |
| High total cholesterol (≥5.1 mmol/L), Week 8 | 61 | 73 |
| High total cholesterol (≥5.1 mmol/L), Week 12 | 56 | 68 |
| High total cholesterol (≥5.1 mmol/L), Week 16 | 61 | 64 |
| High total cholesterol (≥5.1 mmol/L), Week 20 | 61 | 59 |
| High total cholesterol (≥5.1 mmol/L), Week 24 | 56 | 64 |
Improvement in Rheumatoid Arthritis (RA) disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response High sensitivity C-Reactive Protein (hsCRP), and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score less than (\<)3.2, and remission was defined as a DAS28 score \<2.6.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 67 | 55 |
| Week 8 | 89 | 73 |
| Week 12 | 89 | 82 |
| Week 16 | 94 | 77 |
| Week 20 | 94 | 82 |
| Week 24 | 89 | 86 |
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 44 | 27 |
| Week 8 | 67 | 55 |
| Week 12 | 78 | 82 |
| Week 16 | 94 | 68 |
| Week 20 | 89 | 73 |
| Week 24 | 83 | 77 |
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 22 | 9 |
| Week 8 | 28 | 36 |
| Week 12 | 50 | 73 |
| Week 16 | 78 | 46 |
| Week 20 | 72 | 59 |
| Week 24 | 61 | 55 |
Improvement in RA disease activity was measured by the DAS28 score, which is an index combining measurements of swollen and tender joints, acute phase response hsCRP, and global assessment of disease activity by the participant. A clinically meaningful improvement was defined as a reduction of at least 1.2 units in the DAS28 score during the study period. A low disease activity was defined as a DAS28 score \<3.2, and remission was defined as a DAS28 score \<2.6.
| scores on a scale | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Baseline (n=18,21) | 5.0 ± 1.1 | 5.0 ± 0.9 |
| Week 4 (n=18,21) | 3.3 ± 0.8 | 3.6 ± 1.0 |
| Week 8 (n=18,22) | 2.9 ± 0.8 | 3.1 ± 1.2 |
| Week 12 (n=18,22) | 2.6 ± 0.9 | 2.4 ± 1.0 |
| Week 16 (n=18,21) | 2.3 ± 0.4 | 2.6 ± 1.0 |
| Week 20 (n=18,22) | 2.3 ± 0.6 | 2.6 ± 0.9 |
| Week 24 (n=18,22) | 2.3 ± 0.6 | 2.5 ± 1.0 |
ACR20 response is defined as an improvement of ≥20% in swollen joint count (SJC; 66 joints) and tender joint count (TJC; 68 joints) as well as ≥20% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and acute phase reactive factors (Erythrocyte Sedimentation Rate \[ESR\] or C-Reactive Protein \[CRP\]).
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 50 | 41 |
| Week 8 | 67 | 59 |
| Week 12 | 72 | 68 |
| Week 16 | 83 | 77 |
| Week 20 | 83 | 73 |
| Week 24 | 89 | 91 |
ACR50 response is defined as an improvement of ≥50% in SJC (66 joints) and TJC (68 joints) as well as ≥50% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 28 | 18 |
| Week 8 | 28 | 36 |
| Week 12 | 50 | 50 |
| Week 16 | 44 | 46 |
| Week 20 | 67 | 55 |
| Week 24 | 72 | 73 |
ACR70 response is defined as an improvement of ≥70% in SJC (66 joints) and TJC (68 joints) as well as ≥70% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 11 | 5 |
| Week 8 | 17 | 23 |
| Week 12 | 22 | 36 |
| Week 16 | 11 | 27 |
| Week 20 | 22 | 18 |
| Week 24 | 22 | 36 |
ACR90 response is defined as an improvement of ≥90% in SJC (66 joints) and TJC (68 joints) as well as ≥90% improvement in at least 3 of the following 5 remaining ACR assessments: Patient Global Assessment of Pain; Patient Global Assessment of Disease Activity; Physician Global Assessment of Disease Activity; HAQ-DI; and acute phase reactive factors (ESR or CRP).
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 0 | 0 |
| Week 8 | 0 | 9 |
| Week 12 | 0 | 14 |
| Week 16 | 0 | 0 |
| Week 20 | 6 | 5 |
| Week 24 | 6 | 9 |
hsCRP is a marker for inflammation and is measured in milligrams per liter (mg/L). High levels of this protein indicate inflammation in diseases such as RA.
| mg/L | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Screening | 22.8 ± 19.8 | 25.9 ± 36.0 |
| Baseline | 23.5 ± 22.7 | 27.0 ± 32.1 |
| Week 4 | 4.7 ± 6.6 | 3.1 ± 3.4 |
| Week 8 | 3.3 ± 3.3 | 4.5 ± 3.8 |
| Week 12 | 3.2 ± 3.4 | 2.6 ± 3.3 |
| Week 16 | 2.8 ± 3.1 | 3.1 ± 3.3 |
| Week 20 | 2.9 ± 3.0 | 3.0 ± 3.2 |
| Week 24 | 3.2 ± 3.5 | 3.4 ± 3.6 |
M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.
| scores on a scale | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Baseline | 1.29 ± 0.71 | 1.50 ± 0.74 |
| Week 4 | 0.97 ± 0.64 | 1.10 ± 0.64 |
| Week 8 | 0.79 ± 0.67 | 0.95 ± 0.68 |
| Week 12 | 0.80 ± 0.70 | 0.98 ± 0.62 |
| Week 16 | 0.82 ± 0.69 | 0.94 ± 0.69 |
| Week 20 | 0.75 ± 0.61 | 1.05 ± 0.77 |
| Week 24 | 0.68 ± 0.63 | 1.07 ± 0.82 |
M-HAQ is a self-reported, valid assessment of functional disability in RA. Assessment based on ability of participants to perform daily activities in 8 categories: dressing, arising, eating, walking, reaching, gripping, hygiene, and carrying out daily activities. Scores range 0 to 3; without any difficulty=0, with some difficulty=1, with much difficulty=2, unable to do=3.
| Percentage of Participants | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Week 4 | 44.4 | 45.5 |
| Week 8 | 72.2 | 59.1 |
| Week 12 | 72.2 | 54.5 |
| Week 16 | 77.8 | 63.6 |
| Week 20 | 66.7 | 59.1 |
| Week 24 | 72.2 | 50.0 |
Collected over Screening through Week 24 (or early withdrawal). For early withdrawal two follow-up visits occurred; at 4 weeks and at 12 weeks after the last infusion. A telephone call was sufficient for the last visit if laboratory procedures were not needed.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab, Normal Administration | — | 2/22 (9.1%) | 20/22 (90.9%) |
| Tocilizumab, Fast Administration | — | 0/25 (0%) | 17/25 (68%) |
| Event | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| Infective tenosynovitisInfections and infestations | 1/22 | 0/25 |
| Lymphoma cutisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/22 | 0/25 |
| Event | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/22 | 5/25 |
| NeutropeniaBlood and lymphatic system disorders | 1/22 | 4/25 |
| RhinitisInfections and infestations | 3/22 | 0/25 |
| Abdominal pain upperGastrointestinal disorders | 0/22 | 3/25 |
| FatigueGeneral disorders | 2/22 | 3/25 |
| HeadacheNervous system disorders | 1/22 | 3/25 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 2/22 | 3/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/22 | 1/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/22 | 0/25 |
| Urinary tract infectionInfections and infestations | 0/22 | 2/25 |
Intent-to-treat (ITT) Population: All participants enrolled in the study who had been randomly assigned to one of the two study treatments.
| Age, Continuous(years) | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration | Total |
|---|---|---|---|
| Mean | 57.5 ± 11.8 | 59.8 ± 13.1 | 58.7 ± 12.4 |
| Sex: Female, Male(Participants) | Tocilizumab, Normal Administration | Tocilizumab, Fast Administration | Total |
|---|---|---|---|
| Female | 17 | 20 | 37 |
| Male | 5 | 5 | 10 |
The record gives a start of Nov 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab